These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11890361)

  • 1. TAK-637. Takeda.
    Furness JB
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1437-40. PubMed ID: 11890361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eziopitant. Pfizer.
    Evangelista S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1441-3. PubMed ID: 11890362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo.
    Okano S; Nagaya H; Ikeura Y; Natsugari H; Inatomi N
    J Pharmacol Exp Ther; 2001 Aug; 298(2):559-64. PubMed ID: 11454917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pagoclone Indevus.
    Bateson A
    Curr Opin Investig Drugs; 2003 Jan; 4(1):91-5. PubMed ID: 12625036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talnetant GlaxoSmithKline.
    Evangelista S
    Curr Opin Investig Drugs; 2005 Jul; 6(7):717-21. PubMed ID: 16044668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lubiprostone: RU 0211, SPI 0211.
    Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilansetron. Solvay.
    Stacher G
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1432-6. PubMed ID: 11890360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressants: their uses in nonpsychiatric disorders of aging.
    Cunha UV
    Geriatrics; 1986 Oct; 41(10):63-7, 70-1. PubMed ID: 3758682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of TAK-637 on NK(1) receptor-mediated mechanisms regulating colonic secretion.
    Venkova K; Greenwood-Van Meerveld B
    Toxicol Appl Pharmacol; 2004 Apr; 196(2):215-22. PubMed ID: 15081268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia.
    Burnett JR
    Curr Opin Investig Drugs; 2006 Sep; 7(9):850-6. PubMed ID: 17002264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nepadutant Menarini Richerche.
    Ahluwalia A
    Curr Opin Investig Drugs; 2001 Jul; 2(7):919-22. PubMed ID: 11757791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
    Mills DA; Fekrazad HM; Verschraegen CF
    Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional bowel and anorectal disorders in patients with pelvic organ prolapse and incontinence.
    Jelovsek JE; Barber MD; Paraiso MF; Walters MD
    Am J Obstet Gynecol; 2005 Dec; 193(6):2105-11. PubMed ID: 16325624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Another case of doxepin for irritable bowel syndrome.
    Pies RW
    Am J Psychiatry; 1983 Mar; 140(3):368-9. PubMed ID: 6829813
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug treatment options for irritable bowel syndrome: managing for success.
    Dunphy RC; Verne GN
    Drugs Aging; 2001; 18(3):201-11. PubMed ID: 11302287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
    Rupniak NMJ; Kramer MS
    J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 20. What can be done to control incontinence associated with the irritable bowel syndrome?
    Drossman DA
    Am J Gastroenterol; 1989 Apr; 84(4):355-7. PubMed ID: 2929552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.